The Delhi High Court rejects Boehringer Ingelheim’s request for a temporary restraining order, and generic linagliptin production is permitted.

The Delhi High Court rejects Boehringer Ingelheim’s request for a temporary restraining order, and generic linagliptin production is permitted.

In a patent dispute involving the former’s diabetes drug linagliptin, a single judge of the Delhi High Court declined to grant an interim injunction in favour of German pharmaceutical giant Boehringer Ingelheim against Indian generic manufacturers, noting that the patent…